DDInter1447 DDInter1376
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Phentermine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Phentermine {u} (Compound) resembles {v} (Compound) Fenproporex
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Phentermine {u} may lead to a major life threatening interaction when taken with {v} Phenelzine
Phentermine {u} (Compound) treats {v} (Disease) obesity
Phentermine {u} (Compound) binds {v} (Gene) CYP1A2
Phentermine {u} (Compound) upregulates {v} (Gene) TBX2
Phentermine {u} (Compound) is included by {v} (Pharmacologic Class) Increased Sympathetic Activity
Phentermine {u} (Compound) downregulates {v} (Gene) UGDH
Phentermine {u} (Compound) causes {v} (Side Effect) Pulmonary hypertension
Phentermine (Compound) resembles Tranylcypromine (Compound)
Phentermine (Compound) resembles Fenproporex (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Phentermine may lead to a major life threatening interaction when taken with Phenelzine
Phentermine (Compound) treats obesity (Disease)
Phentermine (Compound) binds CYP1A2 (Gene)
Phentermine (Compound) upregulates TBX2 (Gene)
Phentermine (Compound) is included by Increased Sympathetic Activity (Pharmacologic Class)
Phentermine (Compound) downregulates UGDH (Gene)
Phentermine (Compound) causes Pulmonary hypertension (Side Effect)